Definium shares fell 2.1% after the earnings call, a roughly flat reaction. The update included positive Phase 3 findings and regulatory progress, but the next major MDD readout remains ahead: ASCEND top-line data are expected in 2027.
MindMed’s shares fell 5.8% after the Q1 2026 earnings release, reflecting investor disappointment likely tied to cautious outlook and an implied deceleration in near-term progress given no new operational catalysts or guidance updates in the transcript.